A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease ModelsJoseph Kuo, Daren Ure, Daniel J. Trepanier et al.|Journal of Pharmacology and Experimental Therapeutics|2019Cited by 52
Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver miceMichael Bobardt, Philippe Gallay, Patrick Mayo et al.|PLoS ONE|2020Cited by 15
CRV431 decreases diet- and chemical-driven fibrosis in livers of miceJoseph Kuo, Philippe Gallay, Erika Cabrera et al.|Journal of Hepatology|2020Cited by 0
Rencofilstat, a pan-cyclophilin inhibitor, exerts diverse metabolic and transcriptional anti-tumor activities in a murine NASH-HCC modelDaren Ure, Philippe Gallay, Patrick Mayo et al.|Journal of Hepatology|2022Cited by 0
Cyclophilin inhibition with rencofilstat shifts the liver transcriptome and lipidome in preclinical models toward resolution of non-alcoholic steatohepatitisDaren Ure, Robert T. Foster, Winston T Stauffer et al.|Journal of Hepatology|2023Cited by 0